This company no longer operates independently (acquired, merged, or ceased operations). This profile is retained for reference.
Canadian psychedelic drug-discovery company that built the Psybrary, a library of novel psychedelic derivative molecules (psilocybin, DMT, mescaline, MDMA and others) combining synthetic biology and chemistry. It was acquired by Enveric Biosciences in an all-stock deal that closed in September 2021, with MagicMed CEO Joseph Tucker becoming Enveric's CEO. The standalone MagicMed no longer operates independently.
MagicMed Industries News 6 articles
- Enveric Biosciences Announces Closing of MagicMed Industries Acquisition
- MagicMed: Finding the Derivative with Dr. Joseph Tucker
- Enveric Biosciences Announces Agreement to Acquire MagicMed Industries
- MagicMed Industries Announces the Establishment of Psilocybin-Derivatives Portfolio and Launch of Candidate Selection Program
- MagicMed Industries Announces Closing of Upsized and Oversubscribed $8.1 Million Private Placement of Units Led by Gravitas Securities Due to Significant Investor Demand
- MagicMed Industries Closes Oversubscribed Private Placement for $1,642,880 with Mackie Research Capital Corporation